SCHEMBL20135142

SCHEMBL20135142

CC(C)[C@]1(c2ccc(C(=O)N3CCC(n4cc5ccccc5n4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 2/20 0.47
CRBN Q96SW2 2/20 0.38
MAPT P10636 2/20 0.36
BACE1 P56817 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 4/20 0.35
THRB P10828 1/20 0.35
HSD11B1 P28845 1/20 0.35
HTR2B P41595 3/20 0.35
UBE2M P61081 1/20 0.35
DCUN1D1 Q96GG9 1/20 0.35
ADAMTS5 Q9UNA0 1/20 0.35
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
DDB1 Q16531 1/20 0.35
KDM6B O15054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135143 1.00 KDM5A (0.47) KDM5ACRBNMAPTBACE1MEN1
SCHEMBL20809267 0.89 KDM5A (0.38) KDM5ACRBNMEN1KMT2ALMNA
SCHEMBL20135610 0.88 KDM5A (0.38) KDM5ACRBNKMT2AL3MBTL1LMNA
SCHEMBL20135504 0.88 KDM5A (0.38) KDM5AMAPTHSD11B1ADAMTS5ACACB
SCHEMBL20135608 0.88 KDM5A (0.38) KDM5ACRBNKMT2AL3MBTL1LMNA
SCHEMBL20135501 0.88 KDM5A (0.38) KDM5AMAPTHSD11B1ADAMTS5ACACB
SCHEMBL20135378 0.84 TLR8 (0.41) MEN1KMT2AHSD11B1ADAMTS5ACACB
SCHEMBL20135377 0.84 TLR8 (0.41) MEN1KMT2AHSD11B1ADAMTS5ACACB
SCHEMBL20135454 0.80 LMNA (0.62) MAPTL3MBTL1LMNATHRBHTR2B
SCHEMBL20135457 0.80 LMNA (0.62) MAPTL3MBTL1LMNATHRBHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KDM5A 1526/4885CRBN 3363/4885MAPT 4505/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KDM5A 1488/4885CRBN 3419/4885MAPT 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.